Parkinson's disease
Not recruitingStudy on the Effectiveness and Safety of BIIB122 for Patients with Parkinson's Disease
Study on the Effectiveness and Safety of BIIB122 for Patients with Parkinson's Disease
- Disease:Parkinson's disease
- Substances:N2-(3-(2-(2H-1,2,3-Triazol-2-Yl)Propan-2-Yl)-1-Cyclopropyl-1H-Pyrazol-5-Yl)-N4-Ethyl-5-(Trifluoromethyl)Pyrimidine-2,4-Diamine
Italy- Participants:18–64 years · 65+ years
- Substances:N2-(3-(2-(2H-1,2,3-Triazol-2-Yl)Propan-2-Yl)-1-Cyclopropyl-1H-Pyrazol-5-Yl)-N4-Ethyl-5-(Trifluoromethyl)Pyrimidine-2,4-Diamine
- Sponsor:Biogen Idec Research Limited















